Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The future of obesity treatment with GLP-1 agonists will likely depend on continued therapeutic innovation and parallel advances in healthcare policy, delivery systems, and equity-focused implementation strategies
However, my second shipment was sent less than a month after I received my first (Im not sure why), so I developed a backlog of Grns
less than 3 min read Hims & Hers is getting theirs
.webp?t=1743535811)
According to a survey conducted in October 2023 by the International Foundation of Employee Benefit Plans and another by the employee research firm Savanta, only about 1 in 4 employers covered GLP-1 drugs for weight loss in 2023, although both indicate that more employers as many as 43% are planning to offer them as part of their health plans this year
The full report is presented on a personalized web page with identifying information excluded that can easily be shared with their provider or family to discuss treatment options
In theory, the transfer to human milk of GLP-1 agonists may be low, as they are large peptide molecules ( Supplement 3 )
